GAITHERSBURG, Md., April 7, 2014 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, announced today the appointment of Andrew Cohen as Vice President of Marketing. He will have overall marketing responsibilities as the Company moves forward with its commercial plan to launch AutoloGelTM in the wound care market. He will report to Dean Tozer, Executive Vice President and Chief Commercial Officer.
"I am thrilled to welcome Andrew to the Cytomedix team and believe he will be an immediate value-added member of our commercial organization," said Dean Tozer, Executive Vice President and Chief Commercial Officer. "His five years of designing and leading the U.S. marketing organization at Advanced BioHealing perfectly position him to help create the marketing team here at Cytomedix."
Martin Rosendale, Chief Executive Officer added, "Adding world class commercial talent to our organization is one of our top priorities. Andrew's appointment is another example of our plan to build a best in class sales and marketing team to execute on the AutoloGel launch and establish the brand."
Mr. Cohen has more than 15 years of U.S. and international marketing experience in the life sciences industry, including 6 years in the wound care sector. He held several senior commercial positions at Advanced BioHealing Inc., including Director of Marketing, Director of International Marketing and Product Manager. His work there focused primarily on launching and building market share for Dermagraft®. He developed a five-year strategic product plan, including new indication launch planning, brand and message evolution, new channel entry, and new technology market evaluation. He was also instrumental in creating the patient education program, Heal2gether.
Most recently, Mr. Cohen was Vice President of Marketing at Millennium Laboratories, where he established and led cross-functional product management teams in their Medication Monitoring and Genetic Testing franchises through sales and customer support. Earlier in his career, he held positions with Bio-Rad Laboratories, Sequana Therapeutics, and the NASA Ames Research Center. Mr. Cohen earned a Bachelor of Science in Chemical Engineering from the University of California – Los Angeles, and holds a Masters Degree in Pacific and International Affairs from the University of California – San Diego.
About Cytomedix
Cytomedix, Inc. is an autologous regenerative therapies company commercializing innovative platelet technologies for orthopedics and wound care. The Company markets the AutoloGel™ System (AutoloGel.com), a device for the production of autologous platelet rich plasma ("PRP") gel for use on a variety of exuding wounds. For additional information please visit cytomedix.com.
Safe Harbor Statement – Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix' actual results may differ materially due to a number of factors, many of which are beyond Cytomedix' ability to predict or control, including among many others, risks and uncertainties related to the Company's ability to successfully execute its Angel and AutoloGel sales strategies, its expectations relating to the size of the US wound care market as well as its ability to establish and increase its sales and establish the Company's brand in such market, to achieve AutoloGel expected reimbursement rates in 2014 and beyond, and thereafter, the Company's ability to collect the data necessary for the grant of the unconditional coverage, the Company's ability to continue in its efforts to expand in the wound care market, its ability to successfully negotiate with physician offices as anticipated and to realize the anticipated sales growth from such treatments, , to meet its stroke trial enrollment rates, to successfully realize sales of the Angel Technology resulting in the royalty stream to the Company, the Company's ability to successfully integrate the Aldagen acquisition, the Company's ability to expand patient populations as contemplated, its ability to provide Medicare patients with access as expected, the Company's expectations of favorable future dialogue with potential strategic partners, and its ability to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and integrated business enterprise, viability and effectiveness of the Company's sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes", "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2013, as amended to date, and other subsequent filings. These filings are available at www.sec.gov.